Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Clin Pediatr. Jun 9, 2025; 14(2): 100336
Published online Jun 9, 2025. doi: 10.5409/wjcp.v14.i2.100336
Table 4 Comparative analysis of patients with uveitis with unilateral and bilateral involvement
Parameter
Unilateral (n = 67)
Bilateral (n = 82)
P value
Females34 (50.7)49 (59.8)0.321
Age at diagnosis of uveitis (years)0.880
Mean7.17.2
Median (25%, 75%)6.1 (4.4, 8.4)6.5 (4.2, 9.8)
Min–max2.3-17.71.5–16.8
Age at diagnosis of arthritis (years)0.710
Mean6.46.5
Median (25%, 75%)5.7 (3.8, 8.3)5.4 (2.4, 10.4)
Min–max1.2–14.21.0–16.2
Anatomical type of uveitis0.082
Anterior52 (77.6)48 (58.5)
Pars planitis1 (1.5)5 (6.1)
Posterior3 (4.5)5 (6.1)
Panuveitis11 (16.4)24 (29.3)
Manifested (“red-eye”) uveitis32 (47.8)25/62 (40.3)0.042
Human leukocyte antigen-B27 (+)17/34 (50.0)6/38 (15.8)0.002
Eye complications at first examination17 (25.4)29 (35.4)0.215
Antinuclear antibodies positivity33/64 (51.6)47/75 (62.7)0.229
Uveitis appearance0.115
Before arthritis18 (26.9)13 (15.9)
Simultaneously with arthritis9 (13.4)10 (12.2)
After arthritis21 (31.3)38 (46.3)
Unknown1 (1.5)0 (0.0)
Chronic idiopathic uveitis18 (26.9)21 (25.6)
C-reactive protein (mg/L)0.194
Mean23.819.3
Median (25%, 75%)3.7 (1.0, 23.0)1.0 (1.0, 15.2)
Min–max0.1–192.00.0–133.0
ESR (mm/hour)0.086
Mean30.522.7
Median (25%, 75%)24.0 (11.0, 49.0)17.0 (7.0, 26.0)
Min–max4.0–78.02.0–77.0
Active joint at onset0.698
Mean1.91.8
Median (25%, 75%)1.0 (1.0, 2.0)1.0 (1.0, 2.0)
Min–max1.0–6.01.0–7.0